Advaxis Completes Dosing of Vanguard Patient Group in Phase II Cervical Dysplasia Clinical Trial

by Rachel on June 24, 2010

Advaxis Completes Dosing of Vanguard Patient Group in Phase II Cervical Dysplasia Clinical Trial
NORTH BRUNSWICK, N.J.—-Advaxis, Inc., , the live, attenuated Listeria monocytogenes biotechnology company, enrolled and has administered its initial dose to its third patient in its US Food and Drug Administration -approved, phase II clinical trial in cervical intraepithelial neoplasia , commonly known as cervical dysplasia.

Read more on Business Wire via Yahoo! Finance

Leave a Comment

Previous post:

Next post: